Plasma levels of pipecolic acid in patients with chronic liver disease
β Scribed by Hironaka Kawasaki; Tatsuaki Hori; Masako Nakajima; Kenzo Takeshita
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 396 KB
- Volume
- 8
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
Plasma levels of pipecolic acid, which is a minor metabolite of lysine, were determined by high-performance liquid chromatography in 22 patients with chronic liver disease, composed of 6 patients with chronic active hepatitis, 11 with liver cirrhosis and 5 with hepatocellular carcinoma. The plasma levels of pipecolic acid, when compared to those in normal subjects (1.00 +/- 0.08 nmoles per ml), were found to be significantly elevated (p less than 0.01) in patients with liver cirrhosis (1.93 +/- 0.24 nmoles per ml) and hepatocellular carcinoma (2.22 +/- 0.49 nmoles per ml), but did not show any significant change in patients with chronic active hepatitis. Plasma levels of pipecolic acid correlated positively with serum bile acid and bilirubin, and negatively with indocyanine green disappearance rate, cholinesterase and prothrombin time but not with plasma lysine levels. These results suggest that plasma levels of pipecolic acid increase almost parallel to the severity of liver damage, and that this increase in pipecolic acid may reflect the injury of liver peroxisomes which appear to be related to the degradation of pipecolic acid.
π SIMILAR VOLUMES
with consequent organ dysfunction. Carnitine metabolism Carnitine metabolism was studied in 79 patients with could be disturbed by a variety of mechanisms in patients chronic liver disease, including 22 patients with noncirwith chronic liver disease. Dietary intake of carnitine could rhotic liver di
Levels of g1ycoprotein:sialyltransferase activity (EC 2.4.99.1 ; CMP-acetylneuraminate:D-galactosyl-glycoprotein N-acetylneuraminyl-transferase) were measured in plasma of patients with neoplastic disease, and were found elevated above normal control values in 85% of patients examined. There was a c
De novo hepatitis B infection after liver transplantation, in spite of its low prevalence as found by Fabia et al, 1 is of major concern, especially for infected patients and their families. More follow-up time is needed to assess the real impact in morbidity, mortality, and economic costs. Althoug
Infection with putative non-A to E hepatitis virus, designated GB virus C (GBV-C), was surveyed in 286 patients with chronic liver disease in Japan. RNA of GBV-C was detected, by reverse-transcription polymerase chain reaction with nested primers from the 5'-noncoding region, in 19 patients (6.6%) a